Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 12,200 shares, a decline of 27.8% from the August 15th total of 16,900 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily trading volume, of 131,100 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 131,100 shares, the short-interest ratio is currently 0.1 days. Approximately 1.3% of the company’s shares are short sold.

Shuttle Pharmaceuticals Stock Performance

Shares of SHPH stock opened at $3.47 on Tuesday. Shuttle Pharmaceuticals has a one year low of $3.00 and a one year high of $56.25. The company has a 50 day moving average price of $3.63 and a 200 day moving average price of $5.86. The firm has a market capitalization of $3.71 million, a price-to-earnings ratio of -0.84 and a beta of -1.08.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Shuttle Pharmaceuticals to a “strong sell” rating in a research report on Saturday, June 21st.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .